
Featured
Landmark 2026 Breakthrough: Experimental Pancreatic Cancer Drug Doubles Survival Rates in Historic Clinical Trial
A landmark 2026 Phase 3 clinical trial reveals that an experimental stroma-modulating immunotherapy has successfully doubled survival rates for patien...
Read Full Story →